Keryx Biopharmaceuticals specializes in acquiring, developing and commercializing medically important pharmaceutical products to treat renal disease. The company is developing Zerenex (ferric citrate), an oral, ferric iron-based compound with the capability of binding to phosphate and forming non-absorbable complexes. Zerenex’s Phase III clinical program for treating hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration. For more information, visit the company’s Web site at www.keryx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: